Iara Gonçalves de Aquino, Débora Campanella Bastos, Florence Juana Maria Cuadra-Zelaya, Isadora Ferrari Teixeira, Tuula Salo, Ricardo Della Coletta, Edgard Graner, Anticancer properties of the fatty acid synthase inhibitor TVB-3166 on oral squamous cell carcinoma cell lines, Archives of Oral Biology, Volume 113, 2020, 104707, ISSN 0003-9969, https://doi.org/10.1016/j.archoralbio.2020.104707
Anticancer properties of the fatty acid synthase inhibitor TVB-3166 on oral squamous cell carcinoma cell lines
|Author:||Aquino, Iara Gonçalves de1; Bastos, Débora Campanella2; Cuadra-Zelaya, Florence Juana Maria1;|
1Department of Oral Diagnosis, School of Dentistry of Piracicaba, State University of Campinas (UNICAMP), Piracicaba, Sao Paulo, Brazil
2Department of Morphology, School of Dentistry of Piracicaba, State University of Campinas (UNICAMP), Piracicaba, Sao Paulo, Brazil
3Cancer and Translational Medicine Research Unit, Faculty of Medicine and Medical Research Center Oulu, Oulu University Hospital, University of Oulu, Oulu, Finland
4Institute of Oral and Maxillofacial Disease, University of Helsinki, and HUSLAB, Department of Pathology, Helsinki University Hospital, Helsinki, Finland
|Persistent link:|| http://urn.fi/urn:nbn:fi-fe2020050625352
|Publish Date:|| 2021-03-10
Objective: Fatty acid synthase (FASN) is overexpressed in several human cancers, including oral squamous cell carcinoma (OSCC). TVB-3166 is a recently described FASN inhibitor with antitumor effects and potential clinical relevance. The objective of this study was to evaluate the effects of TVB-3166 on OSCC cell lines.
Materials and methods: The OSCC cell line SCC-9 modified to express ZsGreen (ZsG) (SCC-9 ZsG) and its in vivo selected metastatic derivative LN-1A were used to evaluate anticancer properties of TVB-3166. Cell viability was determined using MTT assays and proliferation determined by cell counting in a Neubauer chamber. Cell death and cell cycle progression were analyzed by Annexin V-PE/7-ADD-PerCP labeling and PI staining, respectively. Cell migration was assayed by scratch assays and cell adhesion using myogel. Production of FASN, p-AKT, CPT1-α, and epithelial-mesenchymal transition (EMT) markers were examined by Western blotting.
Results: TVB-3166 significantly reduced cell viability and proliferation, promoted cell cycle arrest and apoptosis, and increased adhesion to myogel in both OSCC cell lines. Finally, the drug reduced SCC-9 ZsG migration.
Conclusion: Our results demonstrated that TVB-3166 has anticancer effects on both SCC-9 ZsG and its metastatic version LN-1A, which are worthy of investigation in preclinical models for OSCC.
Archives of oral biology
|Type of Publication:||
A1 Journal article – refereed
|Field of Science:||
This work was supported by the Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP, 2014/20832-3), Coordenação de Aperfeiçoamento de Pessoal de Nível Superior – Brasil (CAPES) – Finance Code 001, and Conselho Nacional Nacional de Desenvolvimento Científico e Tecnológico (CNPq, 303064/2018-8). The authors thank Marco A. Cavallari Jr for the drawing of Fig. 1A.
© 2020 Elsevier Ltd. All rights reserved. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/.